Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine

Journal of Psychopharmacology

Volumn 18, Issue 3, 2004, Pages 355-365

  Moresco, Rosa Maria ^a   Cavallaro, Roberto ^b   Messa, Cristina ^a   Bravi, Daniele ^c   Gobbo, Clara ^a   Galli, Laura ^d   Lucignani, Giovanni ^e   Colombo, Cristina ^b   Rizzo, Giovanna ^a   Velonà, Isabella ^c   Smeraldi, Enrico ^b   Fazio, Ferruccio ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c Eli Lilly Italia   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Basal ganglia; Clozapine; Emission tomography; Olanzapine; Pituitary; Receptor occupancy

Indexed keywords

3 (2 FLUOROETHYL)SPIPERONE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUORINE 18; OLANZAPINE; SEROTONIN 2 RECEPTOR; 3-N-(2-FLUOROETHYL)SPIPERONE; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; FLUORINE; NEUROLEPTIC AGENT; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SPIPERONE;

ADULT; ARTICLE; BASAL GANGLION; BRAIN CORTEX; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPOPHYSIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; STATISTICAL PARAMETERS; STATISTICAL SIGNIFICANCE; BRAIN; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SCINTISCANNING;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CLOZAPINE; DOUBLE-BLIND METHOD; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN, 5-HT2; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SPIPERONE;

EID: 6044224985     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110401800306     Document Type: Article

References (63)

1. Barnes N M, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083-1152
2. Barrio J R, Satyamurthy N, Huang S C, Keen R E, Nissenson C H, Hoffman J M, Ackermann R F, Bahn M M, Mazziotta J C, Phelps M E (1989) 3-(2′-[18F]fluoroethyl)spiperone: in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans. J Cereb Blood Flow Metab 9: 830-839
3. Bleich A, Brown S L, Kahn R, van Praag H M (1988) The role of serotonin in schizophrenia. Schizophr Bull 14: 297-315
4. Breier A (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 14: 187-202
5. Bressan R A, Jones H M, Ell P J, Pilowsky L S (2001) Dopamine D (2) receptor blockade in schizophrenia. Am J Psychiatry 158: 971-972
6. Bymaster F, Perry K W, Nelson D L, Wong D T, Rasmussen K, Moore N A, Calligaro D O (1999) Olanzapine: a basic science update. Br J Psychiatry 37 (Suppl): 36-40
7. Carlsson A, Waters N, Carlsson M L (1999) Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur Arch Psychiatry Clin Neurosci 249 (Suppl 4): 37-43
8. Coenen H H, Wienhard K, Stocklin G, Laufer P, Hebold I, Pawlik G, Heiss W D (1988) PET measurement of D2 and S2 receptor binding of 3-N-[(2′-18F] fluoroethyl)spiperone in baboon brain. Eur J Nucl Med 14: 80-87
9. Crawford A M, Beasley C M Jr, Tollefson G D (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 26: 41-54
10. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans P M, Linszen D (2003) Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 160: 303-309
11. Eichhammer P, Albus M, Borrmann-Hassenbach M, Schoeler A, Putzhammer A, Frick U, Klein H E, Rohrmeier T (2000) Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet 96: 187-191
12. Farde L, Nordstrom A L, Wiesel F A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-544
13. Fleischhacker W W, Hummer M, Kurz M, Kurzthaler I, Lieberman J A, Pollack S, Safferman A Z, Kane J M (1994) Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 55 (Suppl B): 78-81
14. Friston K J, Frith C D, Liddle P F, Frackowiak R S (1991) Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 11: 690-699
15. Frost J J, Smith A C, Kuhar M J, Dannals R F, Wagner H N Jr (1987) In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors. Life Sci 40: 987-995
16. Gerlach J, Peacock L (1995) New antipsychotics: the present status. Int Clin Psychopharmacol 10 (Suppl 3): 39-48
17. Goffinet A M, Leysen J, Labar D (1990) In vitro pharmacological profile of 3-N-(2-fluoroethyl)spiperone. J Cereb Blood Flow Metab 10: 140-142
18. Goyer P F, Berridge M S, Morris E D, Semple W E, Compton-Toth B A, Schulz S C, Wong D F, Miraldi F, Meltzer H Y (1996) PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med 37: 1122-1127
19. Hagberg G, Gefvert O, Bergstrom M, Wieselgren I M, Lindstrom L, Wiesel F A, Langstrom B (1998) N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Res 82: 147-160
20. Hall H, Farde L, Halldin C, Hurd Y L, Pauli S, Sedvall G (1996) Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 23: 115-123
21. Ito H, Nyberg S, Halldin C, Lundkvist C, Farde L (1998) PET imaging of central 5-HT2A receptors with carbon-11-MDL 100 907. J Nucl Med 39: 208-214
22. Jovkar S, Wienhard K, Coenen H H, Pawlik G, Heiss W D (1991) Quantification of baboon cortical S2 serotonin receptors in vivo with 3-N-(2′-F18)fluoroethylspiperone and positron emission tomography. Eur J Nucl Med 18: 158-163
23. Joyce J N, Gurevich E V (1999) D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Ann NY Acad Sci 877: 595-613
24. Kapur S (1996) 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology (Berl) 124: 35-39
25. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158: 360-369
26. Kapur S, Zipursky R B, Remington G, Jones C, DaSilva J, Wilson A A, Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155: 921-928
27. Kapur S, Zipursky R B, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293
28. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157: 514-520
29. Kasper S, Jones M, Duchesne I (2001) Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol 16: 189-196
30. Kiebel S J, Poline J B, Friston K J, Holmes A P, Worsley K J (1999) Robust smoothness estimation in statistical parametric maps using standardized residuals from the general linear model. Neuroimage 10: 756-766
31. Lerer B, Segman R H, Fangerau H, Daly A K, Basile V S, Cavallaro R, Aschauer H N, McCreadie R G, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy U H, Meltzer H Y, Kennedy J L, Steen V M, Macciardi F (2002) Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27: 105-119
32. Markianos M, Hatzimanolis J, Lykouras L (1999) Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacol 9: 533-536
33. Meisenzahl E M, Dresel S, Frodl T, Schmitt G J, Preuss U W, Rossmuller B, Tatsch K, Mager T, Hahn K, Moller H J (2000) D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. J Psychopharmacol 14: 364-370
34. Meltzer H Y (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21: 106S-1115S
35. Meltzer H Y, Matsubara S, Lee J C (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238-246
36. Mengod G, Villaro M T, Landwehrmeyer G B, Martinez-Mir M I, Niznik H B, Sunahara R K, Seeman P, O'Dowd B F, Probst A, Palacios J M (1992) Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain. Neurochem Int 20 Suppl: 33S-43S
37. Moresco R M, Colombo C, Fazio F, Bonfanti A, Lucignani G, Messa C, Gobbo C, Galli L, Del Sole A, Lucca A, Smeraldi E (2000) Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. Neuroimage 12: 452-465
38. Nordstrom A L, Farde L, Wiesel F A, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33: 227-235
39. Nordstrom A L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444-1449
40. Nordstrom A L, Nyberg S, Olsson H, Farde L (1998) Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch Gen Psychiatry 55: 283-284
41. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L (1999) Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156: 869-875
42. Ozdemir V, Kalow W, Okey A B, Lam M S, Albers L J, Reist C, Fourie J, Posner P, Collins E J, Roy R (2001) Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 21: 603-607
43. Pietrzyk U, Herholz K, Fink G, Jacobs A, Mielke R, Slansky I, Wurker M, Heiss W D (1994) An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 35: 2011-2018
44. Piggott M A, Marshall E F, Thomas N, Lloyd S, Court J A, Jaros E, Costa D, Perry R H, Perry E K (1999) Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine. Neuroscience 90: 433-45
45. Pilowsky L S (2001) Probing targets for antipsychotic drug action with PET and SPET receptor imaging. Nucl Med Commun 22: 829-33
46. Pirker W, Riedl M, Luger A, Czech T, Rossler K, Asenbaum S, Angelberger P, Komhuber J, Deecke L, Podreka I, Brucke T (1996) Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. J Nucl Med 37: 1931-1937
47. Remington G, Kapur S (1999) D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry 60 (Suppl 10): 15-19
48. Schmitt G J, Meisenzahl E M, Dresel S, Tatsch K, Rossmuller B, Frodl T, Preuss U W, Hahn K, Moller H J (2002) Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 1231-iodobenzamide SPECT: a comparative study with olanzapine. J Psychopharmacol 16: 200-206
49. Seeman P, Tallerico T (1998) Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3: 123-134
50. Seeman P, Van Tol H H (1995) Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol 291: 59-66
51. Silvestri S, Seeman M V, Negrete J C, Houle S, Shammi C M, Remington G J, Kapur S, Zipursky R B, Wilson A A, Christensen B K, Seeman P (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152: 174-180
52. Stockmeier C A, DiCarlo J J, Zhang Y, Thompson P, Meltzer H Y (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266: 1374-1384
53. Talairach J, Tournoux P (1988) A co-planar stereotactic atlas of the human brain. Thieme, Thieme
54. Talvik M, Nordstrom A L, Nyberg S, Olsson H, Halldin C, Farde L (2001) No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 755: 926-930
55. 123IIBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl) 141: 175-181
56. Tauscher J, Kapur S, Verhoeff N P, Hussey D F, Daskalakis Z J, Tauscher-Wisniewski S, Wilson A A, Houle S, Kasper S, Zipursky R B (2002) Brain serotonin 5-HT (1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 59: 514-520
57. Turrone P, Kapur S, Seeman M V, Flint A J (2002) Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159: 133-135
58. van Veelen N M, Kahn R S (1999) Dopamine, serotonin, and schizophrenia. Adv Neurol 80: 425-429
59. Westerink B H (2002) Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol 455: 1-18
60. Wienhard K, Coenen H H, Pawlik G, Rudolf J, Laufer P, Jovkar S, Stocklin G, Heiss W D (1990) PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system. J Neural Transm Gen Sect 81: 195-213
61. Woods R P, Cherry S R, Mazziotta J C (1992) Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16: 620-633
62. Worsley K J, Evans A C, Marrett S, Neelin P (1992) A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab 12: 900-918
63. Xiberas X, Martinot J L, Mallet L, Artiges E, Loc H C, Maziere B, Paillere-Martinot M L (2001) Extrastriatal and striatal D (2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 179: 503-508